Q4

Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient's healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations... Our goal at Janux is to provide cancer patients with safe and effective drugs that direct and guide their immune system to eradicate tumors while minimizing safety concerns... At Janux, we are developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient's healthy tissue. We believe that combining Janux's tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient response.

Also known as: Janux, Q4 Inc

Primary location: San Diego United States